Table 4.

Association between covid-19 vaccination or SARS-CoV-2 infection and occurrence of immune mediated neurological disorders of special interest in Spain’s Information System for Research in Primary Care (SIDIAP) database

Event by vaccine and dose	No of participants	Person years	Observed events	Expected events	Standardised incidence ratio (95% CI)
Bell’s palsy
ChAdOx1 nCoV-19:
First dose	592 365	89 055	27	82.6	0.33 (0.22 to 0.48)
Second dose	230 692	55 659	10	47.3	0.21 (0.11 to 0.39)
BNT162b2:
First dose	1 890 434	102 623	100	116.7	0.86 (0.70 to 1.04)
Second dose	1 251 680	74 638	85	97.1	0.88 (0.71 to 1.08)
mRNA-1723:
First dose	244 467	17 648	14	15.2	0.92 (0.54 to 1.55)
Second dose	159 995	12 563	5	11.3	0.44 (0.18 to 1.06)
Ad26.COV2.S:
First dose	120 470	5,228	6	5.2	1.15 (0.52 to 2.56)
SARS-CoV-2 positive test result	288 030	66 603	93	54.7	1.70 (1.39 to 2.08)
Encephalomyelitis
ChAdOx1 nCoV-19:
First dose	592 843	89 121	5	6.1	0.82 (0.34 to 1.97)
Second dose	230 844	55 696	<5	3.4
BNT162b2:
First dose	1 892 409	102 738	9	11.7	0.77 (0.40 to 1.48)
Second dose	1 253 202	74 733	<5	10.3
mRNA-1273:
First dose	244 744	17 669	<5	1.2
Ad26.COV2.S:
First dose	120 588	5,233	<5	0.4
SARS-CoV-2 positive test result	288 374	66 689	17	4.5	3.75 (2.33 to 6.02)
Guillain-Barré syndrome
ChAdOx1 nCoV-19:
First dose	592 860	89 123	<5	5
BNT162b2:
First dose	1 892 423	102 739	5	6.3	0.79 (0.33 to 1.91)
Second dose	1 253 201	74 733	<5	5.3
mRNA-1273:
Second dose	160 213	12,58	<5	0.7
SARS-CoV-2 positive test	288 392	66 693	17	2.9	5.92 (3.68 to 9.53)
Transverse myelitis
BNT162b2:
First dose	1 892 510	102 744	<5	0.9
mRNA-1723:
Second dose	160 222	12 581	<5	0.1

Events with fewer than five occurrences have been omitted for privacy reasons. No events were observed for omitted cohorts.